Genelife Clinical Research Pvt. Ltd. stands out in the clinical research landscape due to its commitment to innovation, global reach, regulatory expertise, transparency, and comprehensive services. Our USP lies in our ability to provide tailored solutions that advance clinical trials efficiently and effectively.
We leverage cutting-edge technology, data-driven insights, and industry best practices at every stage. Our proprietary EDC, randomization, and project management systems ensure superior trial efficiency and transparency.
Extensive experience across oncology, cardiovascular, CNS, dermatology, gastroenterology, ophthalmology, and more — enabling us to address the unique challenges of different disease areas effectively.
Direct offices in India, USA, UK, and Europe — with collaborations in China, Australia, and South Africa. We seamlessly cater to both regional and international clinical research needs.
Long-standing relationships with global regulatory consultants facilitate smooth and expedited approvals — whether for CDSCO, FDA, EMA, TGA, or MHRA requirements.
Sponsors receive transparent, real-time project development tracking — eliminating constant communication burden while keeping all stakeholders fully informed at every milestone.
A full suite covering project management, site management, data management, biostatistics, medical writing, regulatory consulting, pharmacovigilance, and more.
All operations are conducted lawfully, safely, and ethically — reflecting our commitment to the well-being of all clinical trial participants throughout every study.
Each project is unique. Our dedicated team works closely with sponsors to develop custom strategies aligned with specific study requirements, regulatory pathways, and therapeutic objectives.
CDSCO-Registered CRO in India: Our official CDSCO registration (CRO/MH/2026/000159) and registered GENELIFE® trademark underscore our credibility and commitment to the highest regulatory standards. Partner with Genelife for clinical research that is compliant, transparent, and impactful.